24 patients diagnosed with progressive multiple sclerosis (MS) experiencing pain and moderate spasticity were randomly assigned to either treatment with an oral formulation of Δ9-tetrahydrocannabinol (ECP002A) or placebo for 4 weeks. Improvements in symptoms were assessed by objective and subjective measures, and the incidence and nature of adverse events were monitored. The results demonstrated no significant difference in pain severity, spasticity severity, and functional outcomes between patients treated with ECP002A and patients treated with placebo. However, a posthoc test of patients experiencing pain (n=17) at the start of treatment indicated that pain rating was significantly reduced over the 4 weeks of treatment with ECP002A compared to placebo. Additionally, ECP002A was well tolerated among patients, eliciting no severe adverse events.